Syndax Reports Revumenib Achieves 92% Complete Remission Rate in Newly Diagnosed AML Trial
I'm PortAI, I can summarize articles.
Syndax Pharmaceuticals Inc. announced at the ASH Annual Meeting that its menin inhibitor, Revuforj® (revumenib), achieved a 92% complete remission rate in a Phase 1 trial for newly diagnosed AML patients. The trial combined revumenib with intensive chemotherapy. Additional studies showed a 77% overall response rate in relapsed/refractory leukemia patients and positive outcomes in post-transplant maintenance and combination therapies. These findings highlight the potential of revumenib in acute leukemia treatment.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments